UNICHEMLAB530.00

Unichem Laboratories Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersGUFICBIORPGLIFEGUJTHEMSMSPHARMAORCHPHARMAINDSWFTLABSOLARAFDCMcap ₹3,731 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations1,704.92,111.02,201.92,307.9
Other Income31.635.363.171.9
Total Income1,736.52,146.32,264.92,379.7
Expenses
+ Cost of Materials Consumed742.8888.2768.8741.4
+ Purchases of Stock-in-Trade0.9175.8231.5247.8
+ Changes in Inventories-79.1-200.420.275.0
+ Employee Benefit Expense393.1402.2396.6395.6
+ Finance Costs22.721.031.631.7
+ Depreciation & Amortisation113.2124.6125.1123.3
+ Other Expenses547.0580.2600.5619.6
Total Expenses1,740.51,991.72,174.42,234.2
EBITDA100.2264.9184.2228.6
EBIT-13.0140.359.1105.3
Profit
PBT before Exceptional Items-4.1154.690.5145.5
+ Exceptional Items-57.60.0201.9204.9
Pretax Income-61.7154.6292.4350.4
+ Current Tax7.918.34.03.3
+ Deferred Tax0.9-1.235.542.3
Tax Expense8.817.139.545.6
Net Income-70.5137.5252.8304.8
+ Net Income — Continuing Ops-70.5137.5252.8304.8
+ Other Comprehensive Income-5.5-7.012.05.9
Total Comprehensive Income-75.9130.6264.8310.7
Per Share
Basic EPS-10.0119.5335.9144.01
Diluted EPS-10.0119.4735.8543.94
Other Comprehensive Income — detail
+ Other Comprehensive Income-7.012.05.9
+ Items NOT to be Reclassified to P&L-0.31.410.25.6
+ Tax on Items NOT to be Reclassified0.02.62.6
+ Items to be Reclassified to P&L-5.2-8.44.42.9
Per Share — as-filed variants
Basic EPS — Continuing Operations-10.0119.5335.9144.01
Diluted EPS — Continuing Operations-10.0119.4735.8543.94
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit1,040.31,247.31,181.31,243.8
Gross Margin %61.0259.0953.6553.89
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)-4.1154.690.5145.5
− Exceptional Items (reconciliation)-57.60.0201.9204.9
Net Income Adj (tax-effected)-12.9137.578.3126.6
EPS Adj-1.8319.5311.1218.27
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.00
Paid Up Equity Capital14.114.114.114.1
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.